Chidamide as maintenance after chemotherapy or hematopoietic stem cell transplantation in 27 children with T-cell lymphoblastic leukemia: A real-world prospective study

BACKGROUND: The long-term overall survival of children with T-cell acute lymphoblastic leukemia (T-ALL) is limited to approximately 80–85% because of a high incidence of relapse after achieving remission with intensive chemotherapy and hematopoietic stem cell transplantation (HSCT). Novel treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xin-Yu, Han, Xia-Wei, Huang, Ke, Zhang, Ya-Ting, Xu, Hong-Gui, Zhou, Dun-Hua, Xu, Lu-Hong, Fang, Jian-Pei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932021/
https://www.ncbi.nlm.nih.gov/pubmed/36817761
http://dx.doi.org/10.3389/fmed.2023.1096529

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9932021/
https://www.ncbi.nlm.nih.gov/pubmed/36817761
http://dx.doi.org/10.3389/fmed.2023.1096529

Ejemplares similares